Literature DB >> 19836985

Amphotericin B: side effects and toxicity.

Rafael Laniado-Laborín1, Maria Noemí Cabrales-Vargas.   

Abstract

Amphotericin B (AmB) is a crucial agent in the management of serious systemic fungal infections. In spite of its proven track record, its well-known side effects and toxicity will sometimes require discontinuation of therapy despite a life-threatening systemic fungal infection. The mechanism of action of AmB is based on the binding of the AmB molecule to the fungal cell membrane ergosterol, producing an aggregate that creates a transmembrane channel, allowing the cytoplasmic contents to leak out, leading to cell death. Most of the efforts at improving AmB have been focused on the preparation of AmB with a lipid conjugate. AmB administration is limited by infusion-related toxicity, an effect postulated to result from proinflammatory cytokine production. The principal acute toxicity of AmB deoxycholate includes nausea, vomiting, rigors, fever, hypertension or hypotension, and hypoxia. Its principal chronic adverse effect is nephrotoxicity. AmB probably produces renal injury by a variety of mechanisms. Risk factors for AmB nephrotoxicity include male gender, higher average daily dose of AmB (> or = 35 mg/day), diuretic use, body weight > or = 90 kg, concomitant use of nephrotoxic drugs, and abnormal baseline renal function. Clinical manifestations of AmB nephrotoxicity include renal insufficiency, hypokalemia, hypomagnesemia, metabolic academia, and polyuria due to nephrogenic diabetes insipidus. Human studies show convincingly that sodium loading in excess of the usual dietary intake notably reduces the incidence and severity of AmB-induced nephrotoxicity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19836985     DOI: 10.1016/j.riam.2009.06.003

Source DB:  PubMed          Journal:  Rev Iberoam Micol        ISSN: 1130-1406            Impact factor:   1.044


  139 in total

1.  Antifungal activity of Lactobacillus against Microsporum canis, Microsporum gypseum and Epidermophyton floccosum.

Authors:  Jiahui Guo; Brid Brosnan; Ambrose Furey; Elke Arendt; Padraigin Murphy; Aidan Coffey
Journal:  Bioeng Bugs       Date:  2012-03-01

2.  Large-Scale Land Development, Fugitive Dust, and Increased Coccidioidomycosis Incidence in the Antelope Valley of California, 1999-2014.

Authors:  Aaron J Colson; Larry Vredenburgh; Ramon E Guevara; Natalia P Rangel; Carl T Kloock; Antje Lauer
Journal:  Mycopathologia       Date:  2017-01-13       Impact factor: 2.574

3.  The production of reactive oxygen species is a universal action mechanism of Amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drug.

Authors:  Ana Cecilia Mesa-Arango; Nuria Trevijano-Contador; Elvira Román; Ruth Sánchez-Fresneda; Celia Casas; Enrique Herrero; Juan Carlos Argüelles; Jesús Pla; Manuel Cuenca-Estrella; Oscar Zaragoza
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

4.  Renal handling of amphotericin B and amphotericin B-deoxycholate and potential renal drug-drug interactions with selected antivirals.

Authors:  František Trejtnar; Jana Mandíková; Jana Kočíncová; Marie Volková
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

Review 5.  Amphotericin B lipid complex in the management of invasive fungal infections in immunocompromised patients.

Authors:  Matteo Bassetti; Franco Aversa; Filippo Ballerini; Fabio Benedetti; Alessandro Busca; Nicola Cascavilla; Ercole Concia; Andrea Tendas; Francesco Di Raimondo; Patrizio Mazza; Anna Maria Nosari; Giuseppe Rossi
Journal:  Clin Drug Investig       Date:  2011-11-01       Impact factor: 2.859

6.  Proton pump inhibitor-induced hypomagnesemia: A new challenge.

Authors:  Matilda Florentin; Moses S Elisaf
Journal:  World J Nephrol       Date:  2012-12-06

Review 7.  Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight.

Authors:  Humzah Jamshaid; Fakhar Ud Din; Gul Majid Khan
Journal:  J Nanobiotechnology       Date:  2021-04-15       Impact factor: 10.435

8.  Small-molecule suppressors of Candida albicans biofilm formation synergistically enhance the antifungal activity of amphotericin B against clinical Candida isolates.

Authors:  Jianlan You; Lin Du; Jarrod B King; Brian E Hall; Robert H Cichewicz
Journal:  ACS Chem Biol       Date:  2013-02-14       Impact factor: 5.100

9.  Evaluation of amphotericin B and chloramphenicol as alternative drugs for treatment of chytridiomycosis and their impacts on innate skin defenses.

Authors:  Whitney M Holden; Alexander R Ebert; Peter F Canning; Louise A Rollins-Smith
Journal:  Appl Environ Microbiol       Date:  2014-04-25       Impact factor: 4.792

10.  Toxicity mechanisms of amphotericin B and its neutralization by conjugation with arabinogalactan.

Authors:  Sarah Kagan; Diana Ickowicz; Miriam Shmuel; Yoram Altschuler; Edward Sionov; Miriam Pitusi; Aryeh Weiss; Shimon Farber; Abraham J Domb; Itzhack Polacheck
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.